Welcome to our dedicated page for Solid Bioscience SEC filings (Ticker: SLDB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Solid Biosciences Inc. (SLDB) files reports and disclosures with the U.S. Securities and Exchange Commission as a Nasdaq-listed issuer. These SEC filings provide detailed information on the company’s clinical programs, financial condition, risk factors and material corporate events related to its development of precision genetic medicines for rare neuromuscular and cardiac diseases.
Among the documents available, Form 10-K annual reports and Form 10-Q quarterly reports typically discuss Solid Biosciences’ gene therapy pipeline, including SGT-003 for Duchenne muscular dystrophy, SGT-212 for Friedreich’s ataxia, SGT-501 for catecholaminergic polymorphic ventricular tachycardia and SGT-601 for TNNT2-mediated dilated cardiomyopathy, along with its AAV-SLB101 capsid platform and broader development activities. These filings outline the company’s business description, research and development focus and key risks.
Form 8-K current reports, such as the filing describing interim data from the INSPIRE DUCHENNE Phase 1/2 trial of SGT-003, provide updates on material events, including clinical data readouts, regulatory developments, corporate presentations and other significant announcements. Investors can also review information on equity awards and stock plans, as referenced in company communications about inducement grants made under Nasdaq Listing Rule 5635(c)(4).
This SEC filings page offers real-time access to Solid Biosciences’ submissions from the EDGAR system, along with AI-powered summaries that highlight key points from lengthy documents. Users can quickly identify disclosures on clinical trial progress, gene therapy strategy, regulatory interactions and other factors that may be important when evaluating SLDB.
RA Capital and affiliated persons report owning 7,997,510 shares of Solid Biosciences (SLDB), representing approximately 9.9% of the outstanding common stock. The reported position includes 5,673,193 shares directly held by RA Capital Healthcare Fund, L.P., additional small direct holdings through related accounts and pre-funded warrants exercisable for up to 3,722,085 shares subject to a beneficial ownership blocker that prevents exercise above 9.99% ownership. Recent open-market purchases disclosed include 529,768 shares at a weighted-average of $4.49 and smaller buys at prices between $3.80 and $4.50 per share. RA Capital, Peter Kolchinsky and Rajeev Shah disclose shared voting and dispositive power over the reported shares and state delegations of voting/dispositive authority from certain funds.
Solid Biosciences Inc. Schedule 13G/A filing by Commodore Capital entities
Commodore Capital LP and Commodore Capital Master LP filed an amendment to Schedule 13G reporting zero shares beneficially owned of Solid Biosciences Inc. (CUSIP 83422E204), representing 0.0% of the class. The filing lists the issuers' principal office at 500 Rutherford Avenue, Charlestown, Massachusetts, and gives filing addresses for the two filers in New York and the Cayman Islands. Both filers state no sole or shared voting or dispositive power over any shares and certify the securities were not acquired to influence control of the issuer. The filing is signed by Michael Kramarz for both entities and references a Joint Filing Agreement as an exhibit.
Solid Biosciences Inc. (SLDB) reported expanded clinical progress and a strengthened balance sheet while continuing to record sizable operating losses. As of June 30, 2025 the company held $138.9 million in cash and cash equivalents and $129.2 million in available-for-sale securities, totaling $268.1 million of liquid resources (excluding $1.9 million restricted cash). Total assets were $308.3 million and total liabilities were $50.0 million, leaving stockholders' equity of $258.3 million.
The company posted net losses of $39.5 million and $78.8 million for the three and six months ended June 30, 2025, respectively, driven by research and development spending of $32.4 million and $63.3 million for the same periods. Clinical and regulatory milestones include SGT-003 dosing (15 participants dosed as of August 12, 2025) with reported initial biopsy expression of microdystrophin averaging 110%, SGT-212 IND clearance (Dec 2024), and SGT-501 IND clearance and Health Canada CTA approval (July 2025). The February 2025 offering generated approximately $188.0 million of net proceeds. The company expects its cash, cash equivalents and securities to fund operations into the first half of 2027.
Form 4 highlights: On 07/06/2025, Solid Biosciences Inc. (SLDB) director Ian F. Smith acquired 4,573 common shares through the mandatory conversion (Code M) of previously granted restricted stock units (RSUs). The RSUs, issued on 01/06/2025, vest in four equal quarterly tranches and convert to common stock on a 1-for-1 basis. Following the transaction, Smith now directly owns 122,119 common shares and retains 9,146 unvested RSUs. The RSUs will accelerate in full if the Executive Chair Agreement terminates early or upon a change in control of the company. No shares were sold, suggesting continued insider exposure to SLDB’s equity. The filing was signed on 07/08/2025.
Solid Biosciences (NASDAQ:SLDB) filed a routine Form 4 disclosing that director Georgia Keresty received a stock-option grant covering 77,500 shares on 06/12/2025 at an exercise price of $4.58 per share.
The option vests in full on the earlier of the one-year anniversary of the grant or immediately prior to the next annual shareholder meeting, and accelerates upon certain change-in-control events. It expires on 06/12/2035. No open-market purchases or sales of common stock were reported, and Keresty’s beneficial ownership now reflects only the newly granted option, held directly.